Copper Cu 64 Dotatate

Phase 3Small molecule

VVanderbilt-Ingram Cancer Center

Copper Cu 64 Dotatate is one of 8 small molecule programs targeting Neuroendocrine Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine TumorRecruiting

Neuroendocrine TumorPhase 3

Recruiting

Competition

Competitive Landscape

10 competitors in Neuroendocrine Tumor

#DrugCompanyPhaseTrials

Lutathera

AAdvanced Accelerator Applications

Approved

1 2

Avastin

Roche

Phase 3

1 3

Sandostatin

Sun Pharmaceutical Industries, Inc.

Phase 3

1 4

Votrient

Novartis

Phase 2

1 5

Recombinant Human GM-CSF

EEastern Cooperative Oncology Group

Phase 3

1 6

Recombinant Interferon Alfa-2b

SSt. Jude Children's Research Hospital

Phase 3

1 7

Copper Cu 64 Dotatate

VVanderbilt-Ingram Cancer Center

Phase 3

1 8

Alphamedix

OOrano Med LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

ApprovedRecruiting

Neuroendocrine Tumor

NCT06016855

Clinical

Trials by Indication[1]

Neuroendocrine Tumor1 trial

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Recruiting·VVanderbilt-Ingram Cancer Center·Approved·NCT06016855·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Copper Cu 64 Dotatate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Copper Cu 64 Dotatate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Copper Cu 64 Dotatate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt-Ingram Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVanderbilt-Ingram Cancer Center

Copper Cu 64 Dotatate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News